Richa Sharma/X
Sep 3, 2025, 12:48
Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
Richa Sharma, Associate Professor of Neurology at Yale School of Medicine, has shared a post on X:
“Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.”
Title: Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David Tirschwell, Alexander Merkler, Fadi Nahab
Read the full article here.
Find similar posts on Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia